Vertex Pharmaceuticals Inc

6. Aug. 2026, 19:26 UTC

Vertex Pharmaceuticals is trading near unchanged levels with no specific news identified. The stock remains within a narrow range today.

5. Aug. 2026, 19:16 UTC

Vertex Pharmaceuticals shares are higher as Barclays raises its price target to $617. Truist maintains a Buy rating and sets a target of $565.

4. Aug. 2026, 20:05 UTC

Vertex Pharmaceuticals is rising today, buoyed by analyst upgrades and a strong Q2 revenue of $3.33 billion, with TD Cowen raising its target to $550.

3. Aug. 2026, 23:26 UTC

Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, exceeding estimates. The company raised its full-year guidance to between $13.1 billion and $13.2 billion.

31. Juli 2026, 19:56 UTC

Vertex Pharmaceuticals is trading lower amid broader market trends, despite its $10 billion acquisition of Crinetics Pharmaceuticals still pending closure.

30. Juli 2026, 23:26 UTC

Vertex Pharmaceuticals shares are lower in after-market hours, following a notable dip earlier in the session. No specific news was identified to explain the decline.

29. Juli 2026, 23:36 UTC

Vertex Pharmaceuticals Inc shares are higher in after-market trading, recovering from an earlier dip. The stock shows notable volatility within its recent trading range.

28. Juli 2026, 15:22 UTC

Vertex Pharmaceuticals Inc. shares are higher as biotechnology stocks advance. This follows a recent trend of higher daily closes since Monday's close.

27. Juli 2026, 19:51 UTC

Vertex Pharmaceuticals is gaining modestly today amid broader market volatility and a significant decline in crude oil prices affecting overall sentiment.

24. Juli 2026, 13:46 UTC

Vertex Pharmaceuticals is experiencing modest gains amid broader market sentiment influenced by a drop in initial jobless claims to a near 54-year low.

22. Juli 2026, 20:06 UTC

Vertex Pharmaceuticals is lower amid market volatility and uncertainty ahead of the Federal Reserve meeting, reflecting a cumulative decline since Tuesday's close.

20. Juli 2026, 18:41 UTC

Vertex Pharmaceuticals shares are lower amid a broader decline in the Biotechnology sector. The company recently completed a $10 billion acquisition to enhance its portfolio.

17. Juli 2026, 18:56 UTC

Vertex Pharmaceuticals shares are declining amid broader market pressures from rising oil prices and inflation concerns linked to military actions in the Gulf region.

16. Juli 2026, 19:51 UTC

Biotechnology stocks are advancing, supporting Vertex Pharmaceuticals' upward movement. This marks a shift from the recent trend of higher daily closes.

15. Juli 2026, 18:36 UTC

Vertex Pharmaceuticals agrees to acquire Crinetics Pharmaceuticals for $85 per share. Shares are higher as analysts view the deal positively amid easing inflation pressures.

14. Juli 2026, 23:16 UTC

Vertex Pharmaceuticals Inc shares are trading lower in after-market hours, continuing a trend of six consecutive daily declines without any specific news to explain the movement.

13. Juli 2026, 19:06 UTC

Vertex Pharmaceuticals announced an agreement to acquire Crinetics for $85 per share, valued at $10 billion, while shares are lower during Monday's session.

10. Juli 2026, 20:02 UTC

Vertex Pharmaceuticals is lower today amid significant declines in the Biotechnology sub-sector, marking a shift from recent higher daily closes.

9. Juli 2026, 23:16 UTC

Vertex Pharmaceuticals shares are lower in after-market trading, with no specific news identified to explain the movement amid broader market sentiment influenced by U.S.-Iran tensions.

8. Juli 2026, 23:46 UTC

Vertex Pharmaceuticals shares are higher in after-market trading, despite significant declines in European markets amid geopolitical tensions involving the U.S. and Iran.

7. Juli 2026, 19:36 UTC

Vertex Pharmaceuticals shares are lower today following its $10 billion acquisition of Crinetics Pharmaceuticals, despite analyst support and price target increases.

6. Juli 2026, 23:02 UTC

Vertex Pharmaceuticals shares declined in after-market hours following its $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, expected to close in 2026.

2. Juli 2026, 20:03 UTC

Vertex Pharmaceuticals shares are higher following FDA approval for expanded use of CASGEVY, now available for children as young as 2 years old.

1. Juli 2026, 20:06 UTC

Vertex Pharmaceuticals shares are advancing, reflecting broader market trends. The stock remains above its 20-day moving average despite an earlier session pullback.

30. Juni 2026, 20:07 UTC

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.

29. Juni 2026, 19:31 UTC

Vertex Pharmaceuticals is trading higher, driven by positive analyst sentiment and revised earnings estimates ahead of its upcoming earnings report.

26. Juni 2026, 20:04 UTC

Vertex Pharmaceuticals is rising as biotechnology stocks advance during Friday's session. The stock remains above its 20-day moving average after five consecutive higher closes.

25. Juni 2026, 20:02 UTC

Vertex Pharmaceuticals is trading higher today amid notable volatility, reflecting a broader trend since Wednesday's close, despite no specific company news.

24. Juni 2026, 23:26 UTC

Vertex Pharmaceuticals is lower in after-market hours, driven by declines in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

23. Juni 2026, 19:36 UTC

Vertex Pharmaceuticals shares are higher today, recovering from an earlier pullback. The stock remains near the upper end of its one-month trading range.